A restricted stock unit compensation system is being newly established. A monetary claim will be granted to eligible directors as consideration in kind, with ordinary shares issued or disposed. The total amount cap is 3,000 million yen per year, and the total number of shares issued is up to 15,000 shares per year; a transfer restriction period and conditions for gratuitous acquisition are set. Approval by the shareholders’ meeting scheduled for September 25, 2026 is assumed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2385","jir_company_name":"Total Medical Research Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/2385-20260818-02.pdf","jir_short_summary":"A restricted stock unit compensation system is being newly established. A monetary claim will be granted to eligible directors as consideration in kind, with ordinary shares issued or disposed. The total amount cap is 3,000 million yen per year, and the total number of shares issued is up to 15,000 shares per year; a transfer restriction period and conditions for gratuitous acquisition are set. Approval by the shareholders' meeting scheduled for September 25, 2026 is assumed.","jir_summary":"### Purpose and overview of the system\nThis system aims to enhance corporate value on a sustainable basis and share value with shareholders by granting restricted stock unit compensation to targeted directors. The monetary claims paid will be used as in-kind contributed assets to subscribe for and issue or dispose of our ordinary shares. The subscription price will be set based on the closing price immediately prior to the resolution date, within a scope that avoids any particular advantages. During the transfer restriction period, transfers and pledge arrangements are prohibited, and a contract may be concluded in which the company may acquire shares gratuitously under certain conditions.\n\n### Future procedures and approval\nSpecific timing and allocation of grants to targeted directors will be decided by the board of directors' resolution. The agenda related to the introduction of this system will be submitted to the 32nd Annual General Meeting of Shareholders scheduled for September 25, 2026, and will be subject to shareholders' approval. If a stock split or stock consolidation occurs, the total number will be adjusted within a reasonable range.","jir_financial_highlights":"Annual monetary claim cap: 3,000\u767e\u4e07\u5186\u4ee5\u5185 (Unknown)\nTotal number of ordinary shares issued\/disposed: \u5e741.50\u4e07\u682a\u4ee5\u5185 (Unknown)","jir_category":"","jir_hashtags":"#\u7dcf\u533b\u7814\u30db\u30fc\u30eb\u30c7\u30a3\u30f3\u30b0\u30b9, #\u8b72\u6e21\u5236\u9650\u4ed8\u682a\u5f0f\u5831\u916c, #\u5f79\u54e1\u5831\u916c\u5236\u5ea6","jir_key_figures":"Annual monetary claim cap: 3,000\u767e\u4e07\u5186\u4ee5\u5185\nTotal number of ordinary shares issued\/disposed: \u5e741.50\u4e07\u682a\u4ee5\u5185\nApproval date: 2026\u5e749\u670825\u65e5\u958b\u50ac\u4e88\u5b9a\u306e\u682a\u4e3b\u7dcf\u4f1a","jir_meta_title":"Total Medical Research Holdings: Decision to Introduce Restricted Stock Unit Compensation \u2014 Pending Shareholders\u2019 Meeting Approval","jir_meta_description":"Total Medical Research Holdings has resolved to introduce restricted stock unit compensation for directors. It contemplates annual monetary claims up to 3,000 million yen and issuance of up to 15,000 shares annually. Approval by the shareholders\u2019 meeting is required.","jir_og_title":"Total Medical Research Holdings: Restricted Stock Unit Compensation Introduction Resolved","jir_og_description":"Total Medical Research Holdings has resolved to monetize executive compensation via stock-based rewards. Monetary claims will be contributed in kind to issue and dispose of shares. Shareholders\u2019 meeting approval is assumed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59673,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-105127","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n